Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review
The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management. A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were include...
Uložené v:
| Vydané v: | Journal of pain and symptom management Ročník 55; číslo 3; s. 998 - 1003 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.03.2018
Elsevier Limited |
| Predmet: | |
| ISSN: | 0885-3924, 1873-6513, 1873-6513 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.
A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects.
The initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (≤10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time.
Available data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. |
|---|---|
| AbstractList | The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.
A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects.
The initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (≤10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time.
Available data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. Aim. The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management. Methods. A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects. Results. The initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (^10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time. Conclusion. Available data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. AbstractAimThe objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management. MethodsA systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects. ResultsThe initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (≤10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time. ConclusionAvailable data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.AIMThe objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.A systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects.METHODSA systematic literature search on MEDLINE and Embase databases was carried out from each database, setting up the date to August 30, 2017. Studies were included if methadone was a first-line drug as a Step 3 of World Health Organization analgesic ladder, or at low doses (Step 2), if they were conducted in adult patients with cancer pain, and if they contained outcomes on pain- and opioid-related adverse effects.The initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (≤10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time.RESULTSThe initial search yielded 219 records. Ten articles were considered after the initial screening according to inclusion and exclusion criteria. They included three longitudinal open-label studies. In two studies methadone was initiated at low doses (≤10 mg/day). These studies suggested that methadone was effective in providing analgesia and well tolerated as first opioid at different starting doses and in different conditions and settings. Five additional studies were randomized controlled studies with morphine in patients who had received opioids for moderate pain. Methadone, compared with oral morphine, or transdermal fentanyl, either at low (Step 2 level) or relatively higher doses (Step 3 level), provided similar analgesia with similar adverse effects profile with limited dose escalation in time.Available data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs.CONCLUSIONAvailable data are not sufficient to draw net conclusion. However, open-label and controlled studies have shown that methadone may be effective as first-line drug in the management of cancer pain, providing analgesia and adverse effect profiles similar to those produced by other opioids. The finding that methadone doses tend to remain stable suggests that metabolic characteristics and extraopioid analgesic effects, as its well antihyperalgesic properties may be interesting potential advantages. Further studies should provide information regarding the long-term use of methadone or the need to switch from methadone to other opioids when a loss of analgesic response occurs. |
| Author | Mercadante, Sebastiano Bruera, Eduardo |
| Author_xml | – sequence: 1 givenname: Sebastiano orcidid: 0000-0001-9859-6487 surname: Mercadante fullname: Mercadante, Sebastiano email: 03sebelle@gmail.com – sequence: 2 givenname: Eduardo surname: Bruera fullname: Bruera, Eduardo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29101087$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1vEzEQhi1URNPCX0BGXLhsGH-svcsBFEW0IKUKonC2vF4vOOx6g-2A8u_rJS1CkZByGtl-55nxvHOBzvzoLUIvCMwJEPF6M99stfNxPwzazykQme_nOTxCM1JJVoiSsDM0g6oqC1ZTfo4uYtwAQMkEe4LOaZ05UMkZWt_Y9F23mY91xBpfuRBTsXL5vN660bXYebzU3tiAP-Wa-EZ7_c0O1qc3eIFv9zHZQSdn8Gf7y9nfT9HjTvfRPruPl-jr1fsvyw_Fan39cblYFaYkVSo62RrQtW6FrWjDeSlFKVtZNaIRFW-rupGloJpyXbOO8Q4aDryrCKXScGAlu0SvDtxtGH_ubExqcNHYvtfejruoSC2gplJKyNKXR9LNuAs-d6cocJBcUCKz6vm9atcMtlXb4AYd9uphVFnw7iAwYYwx2E4Zl_LPR5-Cdr0ioCZz1Eb9Y46azJme4E-J-ojwUOSU3OUh1-ah5kEHFY2z2ZbWBWuSakd3EuXtEcX0zjuj-x92b-PfuRAVqQJ1Oy3QtD85FcpasgxY_B9wYhN3ZIDZrg |
| CitedBy_id | crossref_primary_10_1007_s40265_025_02189_7 crossref_primary_10_1038_s41598_024_52105_4 crossref_primary_10_1038_s41598_022_21180_w crossref_primary_10_1089_jpm_2022_0455 crossref_primary_10_52965_001c_129552 crossref_primary_10_4103_IJPC_IJPC_109_20 crossref_primary_10_1080_17581869_2025_2494495 crossref_primary_10_25259_IJPC_58_2022 crossref_primary_10_25259_IJPC_383_20 crossref_primary_10_3390_cancers16173015 crossref_primary_10_4103_0973_1075_285690 crossref_primary_10_2217_pgs_2021_0139 crossref_primary_10_11648_j_ijpr_20250101_12 crossref_primary_10_4103_IJPC_IJPC_275_20 crossref_primary_10_1093_oncolo_oyab081 crossref_primary_10_3390_life12050679 crossref_primary_10_1016_j_jopan_2021_08_011 crossref_primary_10_1056_NEJMp2310123 crossref_primary_10_1080_15360288_2019_1666956 crossref_primary_10_1002_jbio_201800468 crossref_primary_10_1016_j_jpain_2020_04_004 crossref_primary_10_1177_10600280211028262 crossref_primary_10_3389_fphar_2024_1438037 crossref_primary_10_1002_smll_202407197 crossref_primary_10_1007_s00520_021_06211_y crossref_primary_10_1146_annurev_physiol_042022_015914 crossref_primary_10_1016_j_lfs_2021_119582 crossref_primary_10_1080_24740527_2019_1660575 crossref_primary_10_1089_jpm_2024_0551 crossref_primary_10_1007_s40263_020_00743_3 crossref_primary_10_2217_pmt_2019_0029 crossref_primary_10_1016_j_jpainsymman_2018_09_008 crossref_primary_10_1038_s41598_024_54009_9 crossref_primary_10_1017_S1478951523001293 crossref_primary_10_1007_s11864_020_0724_4 crossref_primary_10_1016_j_jpainsymman_2024_01_025 |
| Cites_doi | 10.1016/j.critrevonc.2015.12.011 10.1016/j.ejpain.2008.01.013 10.1155/2013/740379 10.1185/03007995.2011.635197 10.1016/0304-3959(93)90125-9 10.1016/j.ejphar.2015.10.049 10.1016/S0140-6736(11)60236-5 10.1200/JCO.1998.16.11.3656 10.1016/S0885-3924(86)80042-2 10.3109/15360288.2014.938883 10.1200/JCO.1996.14.10.2836 10.1016/j.ejca.2016.06.025 10.1016/S1090-3801(97)90064-1 10.1016/S1470-2045(12)70040-2 10.1089/jpm.2014.0266 10.1136/bmj.282.6266.771 10.1016/S0304-3940(97)13391-2 10.1002/cncr.24754 10.1200/JCO.2004.03.172 10.1093/oxfordjournals.annonc.a010679 10.1016/j.jpainsymman.2007.11.003 10.1016/S0885-3924(99)00048-2 10.1089/jpm.2012.0612 10.1016/j.jpainsymman.2015.12.340 10.1111/j.1526-4637.2006.00289.x 10.1089/jpm.2017.0090 |
| ContentType | Journal Article |
| Copyright | 2017 American Academy of Hospice and Palliative Medicine American Academy of Hospice and Palliative Medicine Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. Copyright Elsevier Science Ltd. Mar 2018 |
| Copyright_xml | – notice: 2017 American Academy of Hospice and Palliative Medicine – notice: American Academy of Hospice and Palliative Medicine – notice: Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Science Ltd. Mar 2018 |
| DBID | AAYXX CITATION NPM 7QJ ASE FPQ K6X K9. NAPCQ 7X8 |
| DOI | 10.1016/j.jpainsymman.2017.10.017 |
| DatabaseName | CrossRef PubMed Applied Social Sciences Index & Abstracts (ASSIA) British Nursing Index British Nursing Index (BNI) (1985 to Present) British Nursing Index ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium British Nursing Index Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1873-6513 |
| EndPage | 1003 |
| ExternalDocumentID | 29101087 10_1016_j_jpainsymman_2017_10_017 S0885392417305973 1_s2_0_S0885392417305973 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M ..I .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABUFD ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACJTP ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXBA AFXIZ AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BR6 CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FRJ FYGXN G-2 G-Q GBLVA HDV HMK HMO HVGLF HZ~ IHE J1W J5H KOM LX1 M29 M2W M41 MO0 MOBAO N9A O-L O9- OAUVE OG. OK1 OS- OZT P-8 P-9 P2P PC. Q38 QTD R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNG SNH SPCBC SSH SSN SSZ T5K TR2 UV1 WOW WUQ YYQ Z5R ZGI ZXP ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AADPK AAIAV ABLVK ABVKL ABYKQ AISVY AJBFU LCYCR NAHTW 9DU AAYXX CITATION NPM 7QJ ASE FPQ K6X K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c518t-f7dc0a9ad6e82b4457657d78b6b684d89b7562a24a93f34f0b404f81227c40353 |
| ISICitedReferencesCount | 46 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000426453500040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0885-3924 1873-6513 |
| IngestDate | Sat Sep 27 16:34:35 EDT 2025 Sun Nov 09 14:52:14 EST 2025 Wed Feb 19 02:35:14 EST 2025 Sat Nov 29 07:18:00 EST 2025 Tue Nov 18 22:30:08 EST 2025 Fri Feb 23 02:47:43 EST 2024 Sun Feb 23 10:18:50 EST 2025 Tue Oct 14 19:36:21 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | cancer pain adverse effects strong opioids Methadone opioids for moderate pain opioids |
| Language | English |
| License | This article is made available under the Elsevier license. Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c518t-f7dc0a9ad6e82b4457657d78b6b684d89b7562a24a93f34f0b404f81227c40353 |
| Notes | ObjectType-Article-1 ObjectType-Evidence Based Healthcare-3 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-9859-6487 |
| OpenAccessLink | https://www.clinicalkey.com/#!/content/1-s2.0-S0885392417305973 |
| PMID | 29101087 |
| PQID | 2040746217 |
| PQPubID | 2033110 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1960927770 proquest_journals_2040746217 pubmed_primary_29101087 crossref_citationtrail_10_1016_j_jpainsymman_2017_10_017 crossref_primary_10_1016_j_jpainsymman_2017_10_017 elsevier_sciencedirect_doi_10_1016_j_jpainsymman_2017_10_017 elsevier_clinicalkeyesjournals_1_s2_0_S0885392417305973 elsevier_clinicalkey_doi_10_1016_j_jpainsymman_2017_10_017 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-01 |
| PublicationDateYYYYMMDD | 2018-03-01 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Madison |
| PublicationTitle | Journal of pain and symptom management |
| PublicationTitleAlternate | J Pain Symptom Manage |
| PublicationYear | 2018 |
| Publisher | Elsevier Inc Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Limited |
| References | Bruera, Palmer, Bosnjak (bib28) 2004; 22 Portenoy (bib2) 2011; 377 Weschules, Bain, Richeimer (bib5) 2008; 9 Haumann, Geurts, van Kuijk, Kremer, Joosten, van der Beuken-van Everidngen (bib29) 2016; 65 Mercadante, Casuccio, Agnello, Barresi (bib23) 1999; 18 Hawley, Chow, Fyles, Shokoohi, O'Leary, Mittelstadt (bib19) 2017; 20 Salpeter, Buckley, Bruera (bib20) 2015; 18 van den Beuken-van Everdingen, Hochstenbach, Joosten, Tjan-Heijnen, Janssen (bib1) 2016; 51 Ventafridda Ventafridda, Ripamonti, Bianchi, Sbanotto, De Conno (bib26) 1986; 1 Cruciani (bib6) 2008; 36 Peraino, Mammana, Bertolino (bib25) 2016; 24 Sawe, Hansen, Ginman (bib21) 1981; 282 Wiffen, Wee, Derry, Bell, Moore (bib3) 2017; 7 Mercadante (bib4) 2015; 769 Mercadante, Casuccio, Agnello, Serretta, Calderone, Barresi (bib27) 1998; 16 Caraceni, Hanks, Kaasa (bib30) 2012; 13 Parsons, de la Cruz, El Osta (bib24) 2010; 116 Mercadante, Porzio, Ferrera (bib17) 2008; 12 Bruera, Rico, Bertolino (bib18) 2000; 16 Salpeter, Buckley, Bruera (bib11) 2013; 16 De Conno, Groff, brunelli, Zecca, Ventafridda, Ripamonti (bib22) 1996; 14 Mercadante (bib12) 1997; 1 Good, Afsharimani, Movva, Haywood, Khan, Hardy (bib15) 2014; 28 Mercadante, Bruera (bib7) 2016; 99 Mercadante, Valle, Agnellotti, Caruselli (bib8) 2013; 21 Hawley, Liebscher, Wilford (bib9) 2013; 18 Gorman, Elliott, Inturrisi (bib13) 1997; 223 Mercadante, Sapio, Serretta, Caligara (bib16) 1996; 7 Mercadante, Ferrera, Casuccio (bib10) 2011; 27 Fainsinger, Schoeller, Bruera (bib14) 1993; 52 Hawley (10.1016/j.jpainsymman.2017.10.017_bib19) 2017; 20 Salpeter (10.1016/j.jpainsymman.2017.10.017_bib11) 2013; 16 Fainsinger (10.1016/j.jpainsymman.2017.10.017_bib14) 1993; 52 Hawley (10.1016/j.jpainsymman.2017.10.017_bib9) 2013; 18 Ventafridda Ventafridda (10.1016/j.jpainsymman.2017.10.017_bib26) 1986; 1 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib27) 1998; 16 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib8) 2013; 21 Cruciani (10.1016/j.jpainsymman.2017.10.017_bib6) 2008; 36 Good (10.1016/j.jpainsymman.2017.10.017_bib15) 2014; 28 Weschules (10.1016/j.jpainsymman.2017.10.017_bib5) 2008; 9 Bruera (10.1016/j.jpainsymman.2017.10.017_bib18) 2000; 16 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib23) 1999; 18 van den Beuken-van Everdingen (10.1016/j.jpainsymman.2017.10.017_bib1) 2016; 51 Sawe (10.1016/j.jpainsymman.2017.10.017_bib21) 1981; 282 Haumann (10.1016/j.jpainsymman.2017.10.017_bib29) 2016; 65 Wiffen (10.1016/j.jpainsymman.2017.10.017_bib3) 2017; 7 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib12) 1997; 1 Parsons (10.1016/j.jpainsymman.2017.10.017_bib24) 2010; 116 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib7) 2016; 99 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib10) 2011; 27 Peraino (10.1016/j.jpainsymman.2017.10.017_bib25) 2016; 24 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib4) 2015; 769 De Conno (10.1016/j.jpainsymman.2017.10.017_bib22) 1996; 14 Gorman (10.1016/j.jpainsymman.2017.10.017_bib13) 1997; 223 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib16) 1996; 7 Bruera (10.1016/j.jpainsymman.2017.10.017_bib28) 2004; 22 Salpeter (10.1016/j.jpainsymman.2017.10.017_bib20) 2015; 18 Mercadante (10.1016/j.jpainsymman.2017.10.017_bib17) 2008; 12 Caraceni (10.1016/j.jpainsymman.2017.10.017_bib30) 2012; 13 Portenoy (10.1016/j.jpainsymman.2017.10.017_bib2) 2011; 377 |
| References_xml | – volume: 13 start-page: e58 year: 2012 end-page: e68 ident: bib30 article-title: Use of opioid analgesics in the treatment of cancer pain: evidence-based 14. Recommendations from the EAPC publication-title: Lancet Oncol – volume: 51 start-page: 1070 year: 2016 end-page: 1090 ident: bib1 article-title: Update on prevalence of pain in patients with cancer: systematic review and Meta-analysis publication-title: J Pain Symptom Manage – volume: 377 start-page: 2236 year: 2011 end-page: 2247 ident: bib2 article-title: Treatment of cancer pain publication-title: Lancet – volume: 769 start-page: 71 year: 2015 end-page: 78 ident: bib4 article-title: Opioid metabolism and clinical aspects publication-title: Eur J Pharmacol – volume: 21 start-page: 2225 year: 2013 end-page: 2228 ident: bib8 article-title: The poor use of methadone in Italian hospices publication-title: Support Care Cancer – volume: 16 start-page: 957963 year: 2000 ident: bib18 article-title: A prospective, open study of oral methadone in the treatment of cancer pain publication-title: Proceedings of the 9th World Congress on Pain – volume: 282 start-page: 771 year: 1981 end-page: 773 ident: bib21 article-title: Patient-controlled dose regimen of methadone for chronic cancer pain publication-title: Br Med J – volume: 16 start-page: 616 year: 2013 end-page: 622 ident: bib11 article-title: The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia publication-title: J Palliat Med – volume: 52 start-page: 137 year: 1993 end-page: 147 ident: bib14 article-title: Methadone in the management of cancer pain: a review publication-title: Pain – volume: 18 start-page: 83 year: 2013 end-page: 86 ident: bib9 article-title: Continuing methadone for pain in palliative care publication-title: Pain Res Manag – volume: 116 start-page: 520 year: 2010 end-page: 528 ident: bib24 article-title: Methadone initiation and rotation in the outpatient setting for patients with cancer pain publication-title: Cancer – volume: 27 start-page: 2357 year: 2011 end-page: 2360 ident: bib10 article-title: Outcome of opioid switching 4 weeks after discharge from a palliative care unit publication-title: Curr Med Res Opin – volume: 22 start-page: 185 year: 2004 end-page: 192 ident: bib28 article-title: Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study publication-title: J Clin Oncol – volume: 18 start-page: 188 year: 1999 end-page: 192 ident: bib23 article-title: Methadone response in advanced cancer patients with pain followed at home publication-title: J Pain Symptom Manage – volume: 1 start-page: 203 year: 1986 end-page: 207 ident: bib26 article-title: A randomized study on oral administration of morphine and methadone in the treatment of cancer pain publication-title: J Pain Symptom Manage – volume: 65 start-page: 121 year: 2016 end-page: 129 ident: bib29 article-title: Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer publication-title: Eur J Cancer – volume: 7 start-page: CD012592 year: 2017 ident: bib3 article-title: Opioids for cancer pain–an overview of Cochrane reviews publication-title: Cochrane Database Syst Rev – volume: 16 start-page: 3656 year: 1998 end-page: 3661 ident: bib27 article-title: Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home publication-title: J Clin Oncol – volume: 223 start-page: 5 year: 1997 end-page: 8 ident: bib13 article-title: The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord publication-title: Neurosci Lett – volume: 28 start-page: 197 year: 2014 end-page: 205 ident: bib15 article-title: Therapeutic challenges in cancer pain management: a systematic review of methadone publication-title: J Pain Palliat Care Pharmacother – volume: 14 start-page: 2836 year: 1996 end-page: 2842 ident: bib22 article-title: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients publication-title: J Clin Oncol – volume: 36 start-page: 545 year: 2008 end-page: 552 ident: bib6 article-title: Methadone: to ECG or not to ECG. That is still the question publication-title: J Pain Symptom Manage – volume: 1 start-page: 77 year: 1997 end-page: 83 ident: bib12 article-title: Methadone in cancer pain publication-title: Eur J Pain – volume: 18 start-page: 114 year: 2015 end-page: 119 ident: bib20 article-title: The use of very-low-dose methadone and haloperidol for pain control in the hospital setting: a preliminary report publication-title: J Palliat Med – volume: 20 start-page: 1244 year: 2017 end-page: 1251 ident: bib19 article-title: Clinical outcomes of start-low, Go-slow methadone initiation for cancer-related pain: What's the Hurry? publication-title: J Palliat Med – volume: 99 start-page: 241 year: 2016 end-page: 248 ident: bib7 article-title: Opioid switching in cancer pain: from the beginning to nowadays publication-title: Crit Rev Oncol Hematol – volume: 12 start-page: 1040 year: 2008 end-page: 1046 ident: bib17 article-title: Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management publication-title: Eur J Pain – volume: 7 start-page: 613 year: 1996 end-page: 617 ident: bib16 article-title: Patient-controlled analgesia with oral methadone in cancer pain: preliminary report publication-title: Ann Oncol – volume: 24 start-page: 3351 year: 2016 end-page: 3556 ident: bib25 article-title: Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit publication-title: Support Care cancer – volume: 9 start-page: 315 year: 2008 end-page: 344 ident: bib5 article-title: Actual and potential drug interactions associated with methadone publication-title: Pain Med – volume: 99 start-page: 241 year: 2016 ident: 10.1016/j.jpainsymman.2017.10.017_bib7 article-title: Opioid switching in cancer pain: from the beginning to nowadays publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2015.12.011 – volume: 24 start-page: 3351 year: 2016 ident: 10.1016/j.jpainsymman.2017.10.017_bib25 article-title: Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit publication-title: Support Care cancer – volume: 12 start-page: 1040 year: 2008 ident: 10.1016/j.jpainsymman.2017.10.017_bib17 article-title: Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management publication-title: Eur J Pain doi: 10.1016/j.ejpain.2008.01.013 – volume: 18 start-page: 83 year: 2013 ident: 10.1016/j.jpainsymman.2017.10.017_bib9 article-title: Continuing methadone for pain in palliative care publication-title: Pain Res Manag doi: 10.1155/2013/740379 – volume: 27 start-page: 2357 year: 2011 ident: 10.1016/j.jpainsymman.2017.10.017_bib10 article-title: Outcome of opioid switching 4 weeks after discharge from a palliative care unit publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.635197 – volume: 52 start-page: 137 year: 1993 ident: 10.1016/j.jpainsymman.2017.10.017_bib14 article-title: Methadone in the management of cancer pain: a review publication-title: Pain doi: 10.1016/0304-3959(93)90125-9 – volume: 769 start-page: 71 year: 2015 ident: 10.1016/j.jpainsymman.2017.10.017_bib4 article-title: Opioid metabolism and clinical aspects publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2015.10.049 – volume: 377 start-page: 2236 year: 2011 ident: 10.1016/j.jpainsymman.2017.10.017_bib2 article-title: Treatment of cancer pain publication-title: Lancet doi: 10.1016/S0140-6736(11)60236-5 – volume: 16 start-page: 957963 year: 2000 ident: 10.1016/j.jpainsymman.2017.10.017_bib18 article-title: A prospective, open study of oral methadone in the treatment of cancer pain – volume: 16 start-page: 3656 year: 1998 ident: 10.1016/j.jpainsymman.2017.10.017_bib27 article-title: Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.11.3656 – volume: 1 start-page: 203 year: 1986 ident: 10.1016/j.jpainsymman.2017.10.017_bib26 article-title: A randomized study on oral administration of morphine and methadone in the treatment of cancer pain publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(86)80042-2 – volume: 28 start-page: 197 year: 2014 ident: 10.1016/j.jpainsymman.2017.10.017_bib15 article-title: Therapeutic challenges in cancer pain management: a systematic review of methadone publication-title: J Pain Palliat Care Pharmacother doi: 10.3109/15360288.2014.938883 – volume: 14 start-page: 2836 year: 1996 ident: 10.1016/j.jpainsymman.2017.10.017_bib22 article-title: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.10.2836 – volume: 65 start-page: 121 year: 2016 ident: 10.1016/j.jpainsymman.2017.10.017_bib29 article-title: Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.06.025 – volume: 1 start-page: 77 year: 1997 ident: 10.1016/j.jpainsymman.2017.10.017_bib12 article-title: Methadone in cancer pain publication-title: Eur J Pain doi: 10.1016/S1090-3801(97)90064-1 – volume: 13 start-page: e58 year: 2012 ident: 10.1016/j.jpainsymman.2017.10.017_bib30 article-title: Use of opioid analgesics in the treatment of cancer pain: evidence-based 14. Recommendations from the EAPC publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70040-2 – volume: 18 start-page: 114 year: 2015 ident: 10.1016/j.jpainsymman.2017.10.017_bib20 article-title: The use of very-low-dose methadone and haloperidol for pain control in the hospital setting: a preliminary report publication-title: J Palliat Med doi: 10.1089/jpm.2014.0266 – volume: 21 start-page: 2225 year: 2013 ident: 10.1016/j.jpainsymman.2017.10.017_bib8 article-title: The poor use of methadone in Italian hospices publication-title: Support Care Cancer – volume: 282 start-page: 771 year: 1981 ident: 10.1016/j.jpainsymman.2017.10.017_bib21 article-title: Patient-controlled dose regimen of methadone for chronic cancer pain publication-title: Br Med J doi: 10.1136/bmj.282.6266.771 – volume: 223 start-page: 5 year: 1997 ident: 10.1016/j.jpainsymman.2017.10.017_bib13 article-title: The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord publication-title: Neurosci Lett doi: 10.1016/S0304-3940(97)13391-2 – volume: 116 start-page: 520 year: 2010 ident: 10.1016/j.jpainsymman.2017.10.017_bib24 article-title: Methadone initiation and rotation in the outpatient setting for patients with cancer pain publication-title: Cancer doi: 10.1002/cncr.24754 – volume: 7 start-page: CD012592 year: 2017 ident: 10.1016/j.jpainsymman.2017.10.017_bib3 article-title: Opioids for cancer pain–an overview of Cochrane reviews publication-title: Cochrane Database Syst Rev – volume: 22 start-page: 185 year: 2004 ident: 10.1016/j.jpainsymman.2017.10.017_bib28 article-title: Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study publication-title: J Clin Oncol doi: 10.1200/JCO.2004.03.172 – volume: 7 start-page: 613 year: 1996 ident: 10.1016/j.jpainsymman.2017.10.017_bib16 article-title: Patient-controlled analgesia with oral methadone in cancer pain: preliminary report publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a010679 – volume: 36 start-page: 545 year: 2008 ident: 10.1016/j.jpainsymman.2017.10.017_bib6 article-title: Methadone: to ECG or not to ECG. That is still the question publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2007.11.003 – volume: 18 start-page: 188 year: 1999 ident: 10.1016/j.jpainsymman.2017.10.017_bib23 article-title: Methadone response in advanced cancer patients with pain followed at home publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(99)00048-2 – volume: 16 start-page: 616 year: 2013 ident: 10.1016/j.jpainsymman.2017.10.017_bib11 article-title: The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia publication-title: J Palliat Med doi: 10.1089/jpm.2012.0612 – volume: 51 start-page: 1070 year: 2016 ident: 10.1016/j.jpainsymman.2017.10.017_bib1 article-title: Update on prevalence of pain in patients with cancer: systematic review and Meta-analysis publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2015.12.340 – volume: 9 start-page: 315 year: 2008 ident: 10.1016/j.jpainsymman.2017.10.017_bib5 article-title: Actual and potential drug interactions associated with methadone publication-title: Pain Med doi: 10.1111/j.1526-4637.2006.00289.x – volume: 20 start-page: 1244 year: 2017 ident: 10.1016/j.jpainsymman.2017.10.017_bib19 article-title: Clinical outcomes of start-low, Go-slow methadone initiation for cancer-related pain: What's the Hurry? publication-title: J Palliat Med doi: 10.1089/jpm.2017.0090 |
| SSID | ssj0005363 |
| Score | 2.436928 |
| SecondaryResourceType | review_article |
| Snippet | The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.
A systematic... AbstractAimThe objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.... Aim. The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management. Methods. A... The objective of this review was to assess the existent evidence for the use of methadone as a first-line therapy in cancer pain management.AIMThe objective of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 998 |
| SubjectTerms | adverse effects Analgesia Analgesics Anesthesia Cancer cancer pain Dosage Drugs Escalation Evidence-based medicine Labeling Management Medical screening Methadone Morphine Narcotics Opioids opioids for moderate pain Pain Pain management Pain Medicine Patients Property Public health Side effects strong opioids Systematic review Transdermal fentanyl |
| Title | Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0885392417305973 https://www.clinicalkey.es/playcontent/1-s2.0-S0885392417305973 https://dx.doi.org/10.1016/j.jpainsymman.2017.10.017 https://www.ncbi.nlm.nih.gov/pubmed/29101087 https://www.proquest.com/docview/2040746217 https://www.proquest.com/docview/1960927770 |
| Volume | 55 |
| WOSCitedRecordID | wos000426453500040&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-6513 dateEnd: 20190131 omitProxy: false ssIdentifier: ssj0005363 issn: 0885-3924 databaseCode: AIEXJ dateStart: 19970601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZYhyYkhGDcCmPyJMTLlClxnNiZeKlQK0C9IK2T-mYldiJasSQ0HRr_nuM4N1SKygMvSRTLsePz2f58fI4PQm99n8tIMWURGVBYoHAKfU55FosI00kBVWXUkjGbTvliEXyptmKKMpwAS1N-dxfk_1XU8A6ErV1n_0HczUfhBTyD0OEKYofrXoKfxJuvocqAPIbFeXg-WgK_s8aaTM7yZbZUpZ-flvUa6CM8twYwxkv9qj3bubNxsM1fc525VLv_vMk32U1lCNu1pJnEaxkqLbtSyRrDlKkHlKzVAdzGZZwjbWcCUM26OgiHt0ZYRjFWO8dsO2Vx7llAwWh3wDXn8lbAcjujZ2ACUm-N6kbBsLpY6T-Dn4L_0UZ57ELb5RnXz99P0p7OxOh6PBbz4WL-Lv9u6SBjejO-irhygA4J8wLeQ4eDT8PF59YmyDWh9-paH6Gz1iBwR-m7CM2uBUtJXOaP0aNKYnhgkPIE3YvTY3Q0qWwqjtFDo7nFxiHtKZo1AMJhgUPcAggbAOFlig2AsAYQbgF0iQe4hQ828HmGrkfD-YePVhV2w5KewzdWwpS0wyBUfsxJRCmsSD2mGI_8yOdU8SBiQJpDQsPATVya2BG1aQJEkTBJbddzn6NeCpV8iXASUJfFEVAgP6GxLQPXjlQMjNL1pWRe1Ee8bjshqzPpdWiUb6I2PlyJTrML3ew6CW59RJqsuTmYZZ9Ml7WARO15DHOlAKDtk5n9KXNcVJ2_EI4oiLDFlcaPho8D0ycs2N0-et_krIitIaz7FnxSY0k0ZRGYfRn1iU4-a5JhbtAbfmEaZ7dQH32cJGGM2X30wmCwaSsC6wTH5uzV3z_-Gj1oO_wJ6m1gYHiD7ssfm2WxPkUHbMFPq170C4er5HI |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Methadone+as+a+First-Line+Opioid+in+Cancer+Pain+Management%3A+A+Systematic+Review&rft.jtitle=Journal+of+pain+and+symptom+management&rft.au=Mercadante%2C+Sebastiano&rft.au=Bruera%2C+Eduardo&rft.date=2018-03-01&rft.pub=Elsevier+Limited&rft.issn=0885-3924&rft.volume=55&rft.issue=3&rft.spage=998&rft_id=info:doi/10.1016%2Fj.jpainsymman.2017.10.017&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F08853924%2FS0885392417X00043%2Fcov150h.gif |